Paper cites IceCure's ICE3 interim clinical study results
as evidence of safety and efficacy of cryoablation in early-stage
breast cancer
CAESAREA, Israel, Oct. 25,
2023 /PRNewswire/ -- IceCure
Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the
"Company"), developer of the ProSense® System, a
minimally-invasive cryoablation technology that destroys tumors by
freezing as an alternative to surgical tumor removal, today
announced that a scientific paper titled
"Cryoablation Therapy for Early-Stage Breast Cancer: Evidence and
Rationale" was recently published in the Journal of Breast
Imaging.
Highlights of the paper, which cited the efficacy and safety of
interim results from IceCure's ICE3 study of ProSense® in
early-stage breast cancer, included:
- Technological advances are propelling a paradigm shift toward
less aggressive and less invasive treatment for early-stage breast
cancer
- Patients most likely to benefit from a less aggressive approach
with local therapy are those with small, low-risk tumors
- Cryoablation of breast cancer is an emerging nonsurgical
treatment alternative to breast conserving surgery
- Cryoablation's advantages as compared to surgery include faster
recovery, improved cosmetics, local anesthesia
- Liquid nitrogen based cryoablation system has the advantage of
smaller footprint …relatively in expensive and readily
available
- The best candidates for cryoablation are those with low grade,
hormone receptor positive, and ≤1.5 cm in size tumors
- Further studies are needed to determine longer-term outcomes,
including disease-free and overall survival after cryoablation
therapy
The paper's co-authors include ProSense® users,
Robert C. Ward, MD, Assistant
Professor of Diagnostic Imaging at the Warren Alpert Medical School
of Brown University, Program Director
for the Breast Imaging Fellowship, Associate Chief of Diagnostic
Imaging at Women & Infants Hospital, Providence, Rhode Island; and Alexander B.
Sevrukov, MD, Sidney Kimmel College
of Medicine, Thomas Jefferson
University, Department of Radiology, Division of Breast
Imaging, Philadelphia,
Pennsylvania.
Dr. Ward, a ProSense® user who specializes in
women's imaging and breast tumor cryoablation, commented,
"Combining breast imaging with minimally invasive procedures such
as cryoablation with ProSense® is changing the paradigm of
treatment for breast cancer. We've seen excellent results in
early-stage patients and the growing body of evidence published by
practitioners around the world validates the results we are seeing
first hand."
"We are grateful to the doctors who took the time and care
to assess the literature, write, and publish this independent,
non-sponsored scientific paper. Our interim ICE3 results were a key
part of the data used in this paper and we look forward to
announcing the complete topline data in the first quarter of 2024,"
stated IceCure's CEO, Eyal Shamir.
"Papers like this, combined with several independent studies of
ProSense® cryoablation recently published, help to inform doctors
and patients about how cryoablation can significantly improve
patient outcomes and avoid aggressive treatment when it's not
necessary,"
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets
ProSense®, an advanced liquid-nitrogen-based cryoablation therapy
for the treatment of tumors (benign and
cancerous) by freezing, with the primary focus areas being breast,
kidney, bone and lung cancer. Its minimally invasive technology is
a safe and effective alternative to hospital surgical
tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and
approved to date including in the U.S., Europe, and China.
Forward Looking Statements
This press release contains forward-looking statements
within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses that
cyroablation is changing the paradigm of treatment for breast
cancer, that the Company looks forward to announcing the complete
topline data in the first quarter of 2024, and how cryoablation can
significantly improve patient outcomes and avoid aggressive
treatment when it is not necessary.
Historic results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Because such statements deal with future
events and are based on IceCure's current expectations, they are
subject to various risks and uncertainties and actual results,
performance, or achievements of IceCure could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
many of which are beyond the control of the Company, including
those set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on
March 29, 2023, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/independent-scientific-paper-by-doctors-using-icecures-prosense-published-in-journal-of-breast-imaging-presents-advantages-of-cryoablation-breast-conserving-over-surgery-in-early-breast-cancer-patients-301967131.html
SOURCE IceCure Medical